PL
ALXN

Parkwood LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Parkwood LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,628
Closed -$299K – 141
2021
Q2 		$299K Sell
1,628
-3,472
-68% -$596K 0.03% 115
2021
Q1 		$780K Sell
5,100
-1,299
-20% -$201K 0.14% 81
2020
Q4 		$1M Buy
+6,399
New +$822K 0.12% 91
2015
Q3 		– Sell
-3,588
Closed -$649K – 577
2015
Q2 		$649K Hold
3,588
– – 0.09% 147
2015
Q1 		$622K Hold
3,588
– – 0.08% 159
2014
Q4 		$664K Buy
3,588
+1,292
+56% +$239K 0.09% 110
2014
Q3 		$381K Buy
+2,296
New +$377K 0.08% 166

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Parkwood LLC's ALXN Position: Q3 2021 in Review

Parkwood LLC sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,628 shares — an estimated $299K sold.

Parkwood LLC first reported a position in ALXN in Q3 2014 and held it in 7 quarters. The position peaked at $1M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Parkwood LLC reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Parkwood LLC sold 1,628 Alexion Pharmaceuticals shares in Q3 2021, an estimated $299K.
  • Parkwood LLC first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 7 quarters.
  • Parkwood LLC's Alexion Pharmaceuticals position peaked at $1M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Parkwood LLC's 13F filing for Q3 2021, filed 12 Nov 2021.